Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 18 Jan 2018

Abraham George M, Spooner Linda M

Abstract excerpt

With the advent of the direct-acting antiviral agents (DAAs) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the duration, tolerability, and response to therapy. The DAAs fall into several classes and are variously indicated in the treatment of one or more genotypes of infection. All these agents are orally administered and, as they are largely renally eliminated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carbamates
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 29020275
DOI: 10.1093/cid/cix746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease.PMID 29020275Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Hepatitis C-A clinical review.Semantic proximity Read ↗

[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].Semantic proximity Read ↗

Novel therapies for hepatitis C - one pill fits all?Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

Update on hepatitis C treatment: systematic review of clinical trials.Semantic proximity Read ↗

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Semantic proximity Read ↗

The new era of hepatitis C virus therapy.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.